[go: up one dir, main page]

PL3880660T3 - Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp - Google Patents

Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp

Info

Publication number
PL3880660T3
PL3880660T3 PL19817831.1T PL19817831T PL3880660T3 PL 3880660 T3 PL3880660 T3 PL 3880660T3 PL 19817831 T PL19817831 T PL 19817831T PL 3880660 T3 PL3880660 T3 PL 3880660T3
Authority
PL
Poland
Prior art keywords
compositions
compounds
conditions associated
treating conditions
nlrp
Prior art date
Application number
PL19817831.1T
Other languages
English (en)
Inventor
Shomir Ghosh
Gary Glick
Jason Katz
William Roush
Hans Martin Seidel
Dong-Ming Shen
Shankar Venkatraman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3880660T3 publication Critical patent/PL3880660T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
PL19817831.1T 2018-11-13 2019-11-11 Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp PL3880660T3 (pl)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201862760209P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US201862760244P 2018-11-13 2018-11-13
US201862768811P 2018-11-16 2018-11-16
US201862769165P 2018-11-19 2018-11-19
US201862769151P 2018-11-19 2018-11-19
US201962795919P 2019-01-23 2019-01-23
US201962796356P 2019-01-24 2019-01-24
US201962796361P 2019-01-24 2019-01-24
US201962836577P 2019-04-19 2019-04-19
US201962836575P 2019-04-19 2019-04-19
US201962836585P 2019-04-19 2019-04-19
US201962895595P 2019-09-04 2019-09-04
PCT/US2019/060770 WO2020102096A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (1)

Publication Number Publication Date
PL3880660T3 true PL3880660T3 (pl) 2025-11-12

Family

ID=68841175

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19817831.1T PL3880660T3 (pl) 2018-11-13 2019-11-11 Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp

Country Status (29)

Country Link
US (1) US20230031406A1 (pl)
EP (1) EP3880660B1 (pl)
JP (2) JP7730759B2 (pl)
KR (1) KR20210096123A (pl)
CN (2) CN113166065B (pl)
AU (1) AU2019379109B2 (pl)
BR (1) BR112021008969A2 (pl)
CA (1) CA3114918A1 (pl)
CL (1) CL2021001228A1 (pl)
CO (1) CO2021006075A2 (pl)
CR (1) CR20210235A (pl)
DK (1) DK3880660T3 (pl)
EC (2) ECSP21033236A (pl)
ES (1) ES3042546T3 (pl)
FI (1) FI3880660T3 (pl)
IL (1) IL283042B2 (pl)
JO (1) JOP20210105A1 (pl)
LT (1) LT3880660T (pl)
MA (1) MA54229B1 (pl)
MX (1) MX2021005529A (pl)
MY (1) MY206733A (pl)
PE (1) PE20211698A1 (pl)
PH (1) PH12021500025A1 (pl)
PL (1) PL3880660T3 (pl)
PT (1) PT3880660T (pl)
RS (1) RS67257B1 (pl)
SG (1) SG11202103405TA (pl)
TW (1) TW202031647A (pl)
WO (1) WO2020102096A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11370776B2 (en) * 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
PE20200758A1 (es) 2017-08-15 2020-07-27 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
US12012392B2 (en) 2017-11-09 2024-06-18 Inflazome Limited Sulfonamide carboxamide compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2020018975A1 (en) 2018-07-20 2020-01-23 Genentech, Inc. Sulfonimidamide compounds as inhibitors of interleukin-1 activity
US11976054B2 (en) * 2019-11-12 2024-05-07 Chengdu Baiyu Pharmaceutical Co., Ltd. Amide derivative and preparation method therefore and use thereof in medicine
IL294536A (en) * 2020-01-22 2022-09-01 Hoffmann La Roche Sulfonimidamide compounds as nlrp3 modulators
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
JP2024508728A (ja) * 2021-02-10 2024-02-28 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｎｌｒｐ３阻害剤としての化合物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN116635374B (zh) * 2021-05-10 2025-05-06 康百达（四川）生物医药科技有限公司 酰胺衍生物及其应用
CN116917282A (zh) * 2021-05-10 2023-10-20 成都百裕制药股份有限公司 酰胺衍生物及其应用
WO2022237782A1 (zh) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 酰胺衍生物及其应用
CN114989058B (zh) * 2022-06-02 2024-04-16 中国科学院成都生物研究所 一种手性氯代砜亚胺类化合物及其衍生物的制备方法
CN115974745B (zh) * 2022-12-27 2025-06-03 瑞石生物医药有限公司 一类含引达省的化合物及其医药用途
CN116253664A (zh) * 2023-02-01 2023-06-13 山东海科创新研究院有限公司 基于双液相微乳化缩合工艺的accp制备方法
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055755T2 (hu) * 2015-02-16 2021-12-28 Univ Queensland Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
EP3872070A1 (en) * 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
CN111094242B (zh) * 2017-07-24 2024-02-09 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
FI3658539T3 (fi) * 2017-07-24 2024-05-16 Novartis Ag Yhdisteitä ja koostumuksia nlrp-aktiivisuuteen liittyvien tilojen hoitamiseksi
WO2020018975A1 (en) * 2018-07-20 2020-01-23 Genentech, Inc. Sulfonimidamide compounds as inhibitors of interleukin-1 activity

Also Published As

Publication number Publication date
SG11202103405TA (en) 2021-05-28
MY206733A (en) 2025-01-03
FI3880660T3 (fi) 2025-10-02
WO2020102096A1 (en) 2020-05-22
JOP20210105A1 (ar) 2023-01-30
CN113166065A (zh) 2021-07-23
ECSP21033236A (es) 2021-06-30
IL283042B1 (en) 2024-08-01
CR20210235A (es) 2021-06-30
EP3880660A1 (en) 2021-09-22
JP7730759B2 (ja) 2025-08-28
IL283042B2 (en) 2024-12-01
MA54229A (fr) 2022-02-16
LT3880660T (lt) 2025-10-10
CN113166065B (zh) 2025-04-15
KR20210096123A (ko) 2021-08-04
PE20211698A1 (es) 2021-09-01
JP2024113083A (ja) 2024-08-21
AU2019379109B2 (en) 2022-07-07
US20230031406A1 (en) 2023-02-02
MA54229B1 (fr) 2025-09-30
ES3042546T3 (en) 2025-11-21
PH12021500025A1 (en) 2022-05-02
CA3114918A1 (en) 2020-05-22
ECSP24044340A (es) 2024-07-31
BR112021008969A2 (pt) 2021-08-03
CL2021001228A1 (es) 2021-12-31
JP2022507065A (ja) 2022-01-18
RS67257B1 (sr) 2025-10-31
AU2019379109A1 (en) 2021-05-06
EP3880660B1 (en) 2025-07-02
DK3880660T3 (da) 2025-10-06
CO2021006075A2 (es) 2021-05-31
MX2021005529A (es) 2021-06-18
IL283042A (en) 2021-06-30
TW202031647A (zh) 2020-09-01
CN120531732A (zh) 2025-08-26
PT3880660T (pt) 2025-10-21

Similar Documents

Publication Publication Date Title
ES3042546T3 (en) Compounds and compositions for treating conditions associated with nlrp activity
ZA201908154B (en) Compounds and compositions for treating conditions associated with nlrp activity
PL3468972T3 (pl) Związki i kompozycje do hamowania aktywności shp2
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
PT3484862T (pt) Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia
IL285886A (en) Preparations and methods for the treatment of laminopathy
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL282824A (en) Preparations and methods for treating transient biofilms
SG11202103451YA (en) Compounds and compositions for treating conditions associated with apj receptor activity
IL285796A (en) Methods and preparations for the treatment of cancer
ES3044215T3 (en) Compositions for treating and/or preventing protein-aggregation diseases
SG11202008959RA (en) Composition for improving skin conditions
HK40103462A (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40051035A (en) Compounds and compositions for treating conditions associated with sting activity
HK40048005B (en) Compounds and compositions for treating conditions associated with sting activity
HK40051033A (en) Compounds and compositions for treating conditions associated with sting activity
HK40048003B (en) Compounds and compositions for treating conditions associated with sting activity
IL279550A (en) Ingredients and methods for treating trichomonas
HK40111351A (en) Compounds and compositions for treating conditions associated with apj receptor activity
HK40004368A (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40072218A (en) Compounds and compositions for treating conditions associated with sting activity
HK40072216A (en) Compounds and compositions for treating conditions associated with sting activity
GB2595173B (en) Synergistic composition with anti-proliferative activity
HK40061670B (en) Compounds and compositions for treating conditions associated with apj receptor activity